Erzhi pills reverse PD-L1-mediated immunosuppression in melanoma microenvironment
Background: Cancer immunotherapies aimed at activating immune system, especially by blocking immune checkpoints, have become a successful modality for treating patients with advanced cancers. However, its clinical practice is frequently conceded by high outcomes, low initial response rates and sever...
Main Authors: | Zhirui Fang, Yuejin Xue, Yuze Leng, Lusha Zhang, Xiuyun Ren, Ning Yang, Jing Chen, Lu Chen, Hong Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-02-01
|
Series: | Heliyon |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844024010193 |
Similar Items
-
Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy
by: Katarzyna Tomela, et al.
Published: (2023-03-01) -
Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma
by: Huiyu Yan, et al.
Published: (2023-10-01) -
Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma
by: Jacek Mackiewicz, et al.
Published: (2017-03-01) -
NIVO-TIL: combination anti-PD-1 therapy and adoptive T-cell transfer in untreated metastatic melanoma: an exploratory open-label phase I trial
by: Jean-Matthieu L'Orphelin, et al.
Published: (2024-11-01) -
Granulocyte Apheresis: Can It Be Associated with Anti PD-1 Therapy for Melanoma?
by: Alvise Sernicola, et al.
Published: (2022-10-01)